For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Kura Oncology, Inc.

Calculating rank

USPTO Granted Patents = 34

% Expired Patents = 8.8

EPO Patents = 11

Trademarks = 4

Forward Citations = 100

Loading Chart...

Loading Chart...

40 inventors (with patents filed for the assignee):

Pingda Ren (17 out of 140 patents)

Liansheng Li (15 out of 117 patents)

Tao Wu (15 out of 89 patents)

4. Antonio Gualberto (13 out of 17 patents)

5. Catherine Rose Scholz (11 out of 16 patents)

6. Yi Liu (10 out of 153 patents)

7. Tomasz Cierpicki (10 out of 29 patents)

8. Jolanta Grembecka (10 out of 32 patents)

9. Jonathan Pollock (10 out of 10 patents)

10. Dmitry Borkin (10 out of 16 patents)

11. Jun Feng (9 out of 85 patents)

12. Szymon Klossowski (6 out of 14 patents)

13. Yi Wang (5 out of 41 patents)

14. Patricia Andres (3 out of 6 patents)

15. Roger Paul Bakale (3 out of 3 patents)

Core Competencies:

MENIN Inhibitor

Farnesyltransferase Inhibitors

Hematological Malignancies

Ewing's Sarcoma

Macrocyclic Compounds

Thienopyrimidine

Thienopyridine

Crystalline Forms

Bicyclic Inhibitors

MLL Proteins

Cancer Treatment

Solid Forms

34 patents: Sort by Forward Citations

1. 12521396 - Pharmaceutical compositions comprising a MENIN inhibitor (2026-01-13),

2. 12466835 - Solid forms of macrocyclic compounds, salts and formulations thereof, and methods of preparing and using the same (2025-11-11),

3. 12410184 - Crystalline forms of a menin inhibitor (2025-09-09),

4. 12018011 - Macrocyclic compounds and compositions, and methods of preparing and using the same (2024-06-25),

5. 11944627 - Methods for treating hematological malignancies and Ewing's sarcoma (2024-04-02),

6. RE49687 - Thienopyrimidine and thienopyridine compounds and methods of use thereof (2023-10-10),

7. 11673898 - Substituted inhibitors of menin-MLL and methods of use (2023-06-13),

8. 11672774 - Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors (2023-06-13),

9. 11649251 - Substituted inhibitors of menin-MLL and methods of use (2023-05-16),

10. 11555041 - Bridged bicyclic inhibitors of menin-MLL and methods of use (2023-01-17),

11. 11542248 - Methods and compositions for inhibiting the interaction of menin with MLL proteins (2023-01-03),

12. 11542244 - Synthesis of tipifarnib (2023-01-03),

13. 11541045 - Methods of treating cancer with farnesyltransferase inhibitors (2023-01-03),

14. 11291663 - Methods of treating cancer with farnesyltransferase inhibitors (2022-04-05),

15. 11207314 - Methods of treating cancer patients with farnesyltransferase inhibitors (2021-12-28),

Company Overview

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on the development of innovative medicines for the treatment of cancer. The company specializes in targeted therapies that aim to address specific genetic mutations and pathways in cancer cells, enhancing treatment efficacy while minimizing side effects. Kura's research efforts are centered on advancing its pipeline of drug candidates through various stages of clinical development, contributing to the evolving landscape of oncology therapeutics.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

34 Patents

#184 in San Diego, CA

#2,382 in California

#10,036 in US

#19,674 in the World

San Diego, CA, United States of America

Kura Oncology, Inc.

Forward Citations = 100

40 inventors:

Pingda Ren (17 out of 140 patents)

Liansheng Li (15 out of 117 patents)

Tao Wu (15 out of 89 patents)

4. Antonio Gualberto (13 out of 17 patents)

5. Catherine Rose Scholz (11 out of 16 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Kura Oncology, Inc.. Retrieved from https://idiyas.com/company/kura-oncology

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…